Defence Arranges Financing
Defence Therapeutics (CSE: DTC) (OTCQB: DTCFF) has announced a non-brokered private placement to raise up to $4.2 million through the issuance of up to 7 million units at $0.60 per unit. Each unit consists of one common share and one warrant, with each warrant allowing the purchase of an additional common share at $0.75 for 24 months after closing.
The proceeds will be used to advance preclinical and clinical programs and for general working capital. The company may pay finder's fees, and securities will be subject to a four-month and one-day hold period following closing.
Defence Therapeutics (CSE: DTC) (OTCQB: DTCFF) ha annunciato un collocamento privato non interbancato per raccogliere fino a 4,2 milioni di dollari tramite l'emissione di un massimo di 7 milioni di unità a 0,60 dollari ciascuna. Ogni unità è composta da un'azione ordinaria e un warrant, con ciascun warrant che consente l'acquisto di un'ulteriore azione ordinaria a 0,75 dollari per 24 mesi dopo la chiusura.
I proventi saranno utilizzati per far avanzare programmi preclinici e clinici e per il capitale di lavoro generale. L'azienda potrebbe pagare commissioni ai procacciatori, e i titoli saranno soggetti a un periodo di blocco di quattro mesi e un giorno dopo la chiusura.
Defence Therapeutics (CSE: DTC) (OTCQB: DTCFF) ha anunciado una colocación privada no mediada para recaudar hasta 4,2 millones de dólares mediante la emisión de hasta 7 millones de unidades a 0,60 dólares por unidad. Cada unidad consta de una acción ordinaria y un warrant, con cada warrant que permite la compra de una acción ordinaria adicional a 0,75 dólares durante 24 meses después del cierre.
Los ingresos se utilizarán para avanzar en programas preclínicos y clínicos y para el capital de trabajo general. La empresa puede pagar comisiones a agentes, y los valores estarán sujetos a un período de retención de cuatro meses y un día después del cierre.
Defense Therapeutics (CSE: DTC) (OTCQB: DTCFF)는 중개자 없는 사모 배치를 발표하여 최대 420만 달러를 모금하기 위해 0.60 달러에 최대 700만 개의 유닛을 발행할 예정입니다. 각 유닛은 보통주 한 주와 와런트 하나로 구성되며, 각 와런트는 종료 후 24개월 동안 0.75 달러에 추가 보통주 구매를 허용합니다.
Defence Therapeutics (CSE: DTC) (OTCQB: DTCFF) a annoncé un placement privé sans courtier pour lever jusqu'à 4,2 millions de dollars par l'émission de jusqu'à 7 millions d'unités au prix de 0,60 $ par unité. Chaque unité se compose d'une action ordinaire et d'un bon de souscription, chaque bon permettant d'acheter une action ordinaire supplémentaire à 0,75 $ pendant 24 mois après la clôture.
Les fonds seront utilisés pour faire avancer les programmes précliniques et cliniques ainsi que pour le fonds de roulement général. La société peut payer des commissions de recherche, et les valeurs mobilières seront soumises à une période de blocage de quatre mois et un jour après la clôture.
Defence Therapeutics (CSE: DTC) (OTCQB: DTCFF) hat eine nicht vermittelte Privatplatzierung angekündigt, um bis zu 4,2 Millionen US-Dollar durch die Ausgabe von bis zu 7 Millionen Einheiten zu einem Preis von 0,60 US-Dollar pro Einheit zu beschaffen. Jede Einheit besteht aus einer Stammaktie und einem Warrant, wobei jeder Warrant den Kauf einer zusätzlichen Stammaktie zu 0,75 US-Dollar für 24 Monate nach Abschluss ermöglicht.
Die Einnahmen werden verwendet, um präklinische und klinische Programme voranzutreiben und für das allgemeine Betriebskapital. Das Unternehmen kann Vermittlungsprovisionen zahlen, und die Wertpapiere unterliegen nach dem Abschluss einer Haltedauer von vier Monaten und einem Tag.
- Secured potential funding of up to $4.2 million to advance clinical programs
- Warrant structure provides potential for additional future capital at $0.75 per share
- Dilutive effect on existing shareholders through issuance of up to 7 million new units
- Offering price of $0.60 per unit may represent a discount to market price
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce a non-brokered private placement of up to
Each Unit is comprised of one common share in the capital of the Company and one common share purchase warrant (each, a "Warrant"). Each Warrant will entitle the holder thereof to acquire one additional common share at a price of
The Company intends to use the net proceeds to advance its preclinical and clinical programs, and for general working capital. The Company may pay a finder's fee in connection with the Offering in accordance with the policies of the CSE. The securities issued in connection with the Offering will be subject to a statutory hold period of four months and one day following the closing date in accordance with the CSE.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235671
FAQ
How much is Defence Therapeutics (DTCFF) raising in its private placement?
What are the terms of the DTCFF warrants in the December 2024 offering?
How will Defence Therapeutics use the proceeds from its $4.2M private placement?
What is the holding period for securities issued in Defence Therapeutics' private placement?
